Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports

The management of castrate-resistant prostate cancer progressing after maximum androgen blockade (MAB) has evolved in the last decade with the development of several novel therapeutic options. However, the initial therapeutic strategy in these patients usually involves withdrawal of anti-androgen th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hingorani, Mohan, Dixit, Sanjay, Bashir, Fahim, Butt, Mohammad, Hawkyard, Simon, Khafagy, Richard, Robertson, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296085/
https://www.ncbi.nlm.nih.gov/pubmed/25610714
http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296085/
https://www.ncbi.nlm.nih.gov/pubmed/25610714
http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.007

Ejemplares similares